NXTM - Nxstage Medical, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
26.10
+0.38 (+1.48%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close25.72
Open25.73
Bid0.00 x 0
Ask0.00 x 0
Day's Range25.53 - 26.19
52 Week Range20.45 - 30.80
Volume468,410
Avg. Volume607,720
Market Cap1.731B
Beta0.24
PE Ratio (TTM)N/A
EPS (TTM)-0.22
Earnings DateNov 1, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Trade prices are not sourced from all markets
  • ACCESSWIRE9 days ago

    Wired News - US Release of MasterGuard(R) Plus Announced by Nxstage Medical

    Stock Monitor: Milestone Scientific Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 17, 2018 / Active-Investors.com has just released a free research report on Nxstage Medical, Inc. (NASDAQ: NXTM ...

  • See what the IHS Markit Score report has to say about NxStage Medical Inc.
    Markit10 days ago

    See what the IHS Markit Score report has to say about NxStage Medical Inc.

    NxStage Medical Inc NASDAQ/NGS:NXTM

  • Medisystems Announces US Release of MasterGuard® Plus
    PR Newswire13 days ago

    Medisystems Announces US Release of MasterGuard® Plus

    Innovative AVF needle guard includes enhancements designed to prevent needlesticks LAWRENCE, Mass. , April 13, 2018 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company ...

  • See what the IHS Markit Score report has to say about NxStage Medical Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about NxStage Medical Inc.

    NxStage Medical Inc NASDAQ/NGS:NXTM

  • NxStage Celebrates Fifth Annual National Home Hemodialysis Day
    PR Newswirelast month

    NxStage Celebrates Fifth Annual National Home Hemodialysis Day

    Company lights Boston's Zakim Bridge and boosts educational awareness efforts on the benefits of home hemodialysis and more frequent therapy. LAWRENCE, Mass., March 15, 2018 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), the manufacturer of the NxStage® System One™ home hemodialysis system, is celebrating the fifth annual Home Hemodialysis (HHD) Day on March 15, 2018. Annually observed during National Kidney Month, this initiative focuses on raising awareness of home hemodialysis and more frequent therapy as a viable treatment option for patients requiring dialysis.

  • Seven Unique NxStage Abstracts Presented During the 38th Annual Dialysis Conference
    PR Newswirelast month

    Seven Unique NxStage Abstracts Presented During the 38th Annual Dialysis Conference

    LAWRENCE, Mass., March 13, 2018 /PRNewswire/ -- NxStage Medical, Inc. (NXTM), a leading medical technology company focused on advancing renal care, announced new findings further demonstrating the benefits of home hemodialysis with the NxStage® System One™, including on-site hemodialysis at skilled nursing facilities, solo home hemodialysis, and more frequent home hemodialysis. Eric Weinhandl, PhD, MS, NxStage Clinical Epidemiologist and Adjunct Assistant Professor at the University of Minnesota, presented a study of hospitalization and related Medicare expenditures in the roughly 8,000 nursing home residents per year who initiated dialysis.

  • GlobeNewswire2 months ago

    Recent Analysis Shows ILG, Diamond Offshore Drilling, Interactive Brokers Group, NxStage Medical, Broadridge Financial Solutions, and ServiceNow Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, March 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Why Abiomed’s Product Pipeline Looks Promising
    Market Realist2 months ago

    Why Abiomed’s Product Pipeline Looks Promising

    Abiomed (ABMD) is strategically focused on the market penetration of the company’s family of Impella heart pumps. The Impella device portfolio consists of Impella 2.5, Impella CP, Impella RP, Impella LD, and Impella 5.0 devices. To this end, Abiomed discontinued the sale of its AB5000 device used for heart surgery.

  • What Analysts Recommend for Abiomed and Peers in February 2018
    Market Realist2 months ago

    What Analysts Recommend for Abiomed and Peers in February 2018

    Abiomed (ABMD) is a supplier of mechanical circulatory support devices and offers a continuum of care to heart failure patients. Abiomed develops, manufactures, and commercializes products designed to improve the blood flow and perform the pumping function of the heart. Of the ten analysts covering Abiomed (ABMD) in February 2018, five analysts have given the stock a “strong buy” rating, three analysts have given it a “buy” rating, while two analysts have given it a “hold” rating.

  • Wider Losses Worry NxStage Medical Shareholders
    Motley Fool2 months ago

    Wider Losses Worry NxStage Medical Shareholders

    An increasing discount to the buyout price for the dialysis specialist's stock is raising concerns.

  • A Look at NxStage Medical’s Business Strategy
    Market Realist2 months ago

    A Look at NxStage Medical’s Business Strategy

    At present, in-center hemodialysis is the predominant ESRD (end stage renal disease) therapy in the United States. According to NxStage Medical (NXTM), ~10%–15% of ESRD patients in the United States would be appropriate candidates for the company’s home dialysis equipment, System One. According to Centers for Medicare and Medicaid (or CMS), only 18% of dialysis clinics in the United States actively offer home hemodialysis for patients, and only 27% are certified to offer this therapy.

  • Insight into the NxStage Medical–Fresenius Medical Care Merger
    Market Realist2 months ago

    Insight into the NxStage Medical–Fresenius Medical Care Merger

    Since its inception, NxStage Medical (NXTM) has focused on creating a long-term sustainable model driven by innovative technologies. Although NxStage Medical has witnessed revenue growth, it has historically operated at a net loss. It expects the operating income it generates from its products business to continue to be offset by the losses in its kidney care business and the costs associated with its merger with Fresenius Medical Care Holdings (FAS).

  • Analysts’ Ratings for NxStage Medical and Peers in February 2018
    Market Realist2 months ago

    Analysts’ Ratings for NxStage Medical and Peers in February 2018

    Headquartered in Lawrence, Massachusetts, NxStage Medical (NXTM) is a medical technology company with a focus on developing, manufacturing, and marketing innovative products targeted at patients suffering from chronic or acute kidney failure. The company also operates NxStage kidney care dialysis centers, which treat end-stage renal disease (or ESRD) patients. NxStage Medical’s primary product is System One, which is capable of delivering the therapeutic flexibility and clinical benefits of traditional dialysis machines in a smaller, portable, and easy-to-use format.

  • Barrons.com2 months ago

    [$$] Big Stock Buys: Bluebird, Walgreens, Mallinckrodt

    Hedge fund Deerfield Management was fresh off a settlement with the Securities and Exchange Commission as the fourth quarter began. As the fourth quarter played out, Deerfield got back to making investment moves in health care and biotech. Deerfield initiated positions in Walgreens Boots Alliance (WBA) and Bluebird Bio (BLUE), more than tripled its holdings in Mallinckrodt (MNK), sold a fifth of its Mylan (MYL) investment, and exited NxStage Medical (NXTM) altogether.

  • See what the IHS Markit Score report has to say about NxStage Medical Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about NxStage Medical Inc.

    NxStage Medical Inc NASDAQ/NGS:NXTM

  • NxStage Medical, Inc. :NXTM-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
    Capital Cube4 months ago

    NxStage Medical, Inc. :NXTM-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017

    Categories: Yahoo FinanceGet free summary analysis NxStage Medical, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of NxStage Medical, Inc. – Rockwell Medical, Inc., Fresenius Medical Care AG & Co. KGaA Sponsored ADR, Cantel Medical Corp., C. R. Bard, Inc., Baxter International Inc., Nephros, Inc., ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about NxStage Medical Inc.
    Markit4 months ago

    See what the IHS Markit Score report has to say about NxStage Medical Inc.

    NxStage Medical Inc NASDAQ/NGS:NXTM

  • NxStage Nx2me Connected Health Improves Home Hemodialysis
    Zacks4 months ago

    NxStage Nx2me Connected Health Improves Home Hemodialysis

    NxStage Medical (NXTM) consistently looks to expand dialysis platform.

  • PR Newswire4 months ago

    NxStage Celebrates Over 5,000 Home Hemodialysis Patients Receiving Kidney Transplants

    "The more I realize how things have changed for the better, the more amazed I am," said Maria Jimenez, a former NxStage patient. "Switching from in-center to home hemodialysis with NxStage System One was life-changing for me. Soon after I started dialyzing more often at home, I noticed I felt better and had more energy.  I am extremely thankful for everything home hemodialysis has given me, and I know more frequent treatments got me where I am today.

  • NxStage Celebrates Over 5,000 Home Hemodialysis Patients Receiving Kidney Transplants
    CNW Group4 months ago

    NxStage Celebrates Over 5,000 Home Hemodialysis Patients Receiving Kidney Transplants

    NxStage Celebrates Over 5,000 Home Hemodialysis Patients Receiving Kidney Transplants

  • Nx2me Connected Health® Improves Home Hemodialysis Retention
    PR Newswire5 months ago

    Nx2me Connected Health® Improves Home Hemodialysis Retention

    In the study, outcomes among 606 Nx2me users and contemporary matched controls were compared.1 Nx2me users comprised both patients already established on home hemodialysis with the NxStage System One and new home hemodialysis patients. A key component of the Nx2me platform is the Nx2me iPad® app, which is designed to increase patients' ease of use of home therapy by capturing treatment data and wirelessly sending it to their center after each treatment, thereby reducing the need for paper flow sheets.

  • See what the IHS Markit Score report has to say about NxStage Medical Inc.
    Markit5 months ago

    See what the IHS Markit Score report has to say about NxStage Medical Inc.

    NxStage Medical Inc NASDAQ/NGS:NXTM

  • See what the IHS Markit Score report has to say about NxStage Medical Inc.
    Markit5 months ago

    See what the IHS Markit Score report has to say about NxStage Medical Inc.

    NxStage Medical Inc NASDAQ/NGS:NXTM

  • Reuters5 months ago

    Prospect of tougher antitrust regulation worries deal investors

    The top U.S. antitrust regulator has sent a chilling message to dealmakers with his opposition to AT&T Inc buying Time Warner Inc: Companies do not have to be competitors for their merger to hurt competition, and there are no simple fixes to get such deals approved. The Department of Justice's lawsuit to block the AT&T purchase could be a negative sign for other so-called "vertical" mergers - where the companies do not compete but one supplies the other - such as pharmacy operator CVS Health Corp's plan to buy insurer Aetna Inc. Investors had thought AT&T's acquisition of Time Warner, if not a slam dunk, would be approved by the Justice Department and its antitrust division chief Makan Delrahim with relatively few asset sales or conditions.